Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

DISEASE CHARACTERISTICS: Phase I (closed to accrual as of 10/15/2007) Histologically or cytologically confirmed solid tumor or hematologic malignancy, including, but not limited to, any of the following: Breast cancer Ovarian cancer Myeloid or lymphoid leukemia Hodgkin or non-Hodgkin lymphoma Multiple myeloma Measurable or evaluable disease Must meet 1 of the following criteria: Refractory to at least one prior conventional treatment regimen Not a candidate for conventional therapy No conventional therapy exists No clinically or radiographically significant pleural or pericardial effusion Patients with ascites may be eligible at the discretion of the investigator Previously treated central nervous system disease allowed provided it has been stable for > 3 months and it is not the only site of measurable disease Not eligible for a higher priority protocol Phase II Diagnosis of breast cancer Metastatic disease Measurable disease by RECIST criteria No symptomatic brain metastases Patients with treated brain metastases that have been stable for > 3 months and does not require chronic steroids are eligible Hormone receptor status not specified PATIENT CHARACTERISTICS: Phase I (closed to accrual as of 10/15/2007) Karnofsky performance status 60-100% Life expectancy ≥ 2 months Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception WBC ≥ 2,000/mm³ ANC ≥ 1,500/mm³ (≥ 1,000/mm³ for patients with marrow infiltration) Platelet count ≥ 100,000/mm³ (≥ 50,000/mm³ for patients with marrow infiltration) Hemoglobin ≥ 8 g/dL Creatinine ≤ 2.5 mg/dL OR creatinine clearance ≥ 30 mL/min AST and ALT < 2.5 times upper limit of normal (ULN) Total bilirubin < 1.2 times ULN Prothrombin time (PT) and activated partial thromboplastin time (aPTT) < 1.5 times ULN Patients receiving warfarin or heparin therapy for a history of thrombosis, embolism, or other indication must have PT and/or aPTT within the accepted therapeutic ranges for those indications Patients with a history of reactions to other liposomal drug formulations that are not due to the liposome itself may be eligible at the discretion of the investigator No known HIV seropositivity No known active hepatitis A, B, or C viral infection No New York Heart Association class III or IV congestive heart failure LVEF ≥ 45% by 2-D ECHO or MUGA No acute ischemia or new conduction system abnormality by EKG No conduction system abnormality (e.g., left bundle branch block) by EKG that would preclude the ability to detect new ischemic episodes No myocardial infarction within the past 6 months No significant comorbidity, such as poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that, in the opinion of the investigator, might compromise any aspect of the study No uncontrolled infection Patients may have febrile episodes up to 38.5°C if these are felt to be due to tumor fever and the possibility of infection has been ruled out by evaluation No prior hypersensitivity reaction to pegylated doxorubicin hydrochloride liposome or doxorubicin hydrochloride Patients with a history of reactions to other liposomal drug formulations and/or to the liposome itself, as opposed to the encapsulated agent, may be excluded at the discretion of the investigator Phase II Female or male Menopausal status not specified Karnofsky performance status 70-100% Life expectancy ≥ 3 months Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after completion of study therapy ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 2.5 mg/dL (≤ 200 µmol/L) AST and ALT ≤ 2 times ULN Alkaline phosphatase ≤ 2 times ULN (unless attributed to tumor) Bilirubin ≤ ULN Cardiac ejection fraction > 50% by MUGA or 2-D ECHO No clinical evidence of congestive heart failure No New York Heart Association class II-IV cardiac disease No myocardial infarction within the past 6 months No uncontrolled angina No severe uncontrolled ventricular arrhythmias No evidence of acute ischemia or active conduction system abnormalities by EKG Any EKG abnormality at screening must be documented by the investigator as not medically relevant No grade 2 peripheral neuropathy within the past 14 days No significant comorbidity that would impair compliance with study therapy or interpretation of study results No history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride or the components of pegylated doxorubicin hydrochloride liposome No hypersensitivity to bortezomib, boron, or mannitol No serious medical or psychiatric illness likely to interfere with participation in this study PRIOR CONCURRENT THERAPY: Phase I (closed to accrual as of 10/15/2007) More than 3 weeks since prior major surgery More than 3 weeks since prior and no concurrent radiotherapy More than 4 weeks since prior and no concurrent immunotherapy (i.e., interferon, interleukin, or other cytokine-based treatment) More than 3 weeks since prior and no concurrent participation in another therapeutic clinical trial with an experimental drug More than 3 weeks since prior and no other concurrent chemotherapy No prior doxorubicin dose > 400 mg/m² No other concurrent antineoplastic therapy Phase II More than 6 months since prior anthracyclines More than 14 days since other prior investigational drugs No more than 300 mg/m² of prior doxorubicin or 540 mg/m² of prior epirubicin No more than two prior chemotherapy regimens for metastatic disease No other concurrent antineoplastic therapy